Biowaiver for Immediate and Modified Release Dosage forms Scientific summary of the CSPS workshop

Abstract

A joint Canadian Society for Pharmaceutical Sciences and Health Canada workshop entitled “Biowaiver for Immediate and Modified Release Dosage forms” was held in Ottawa, November 19th 2015. A summary of all presentations is included.

Repositioning study of flubendazole for treating lung cancer and meningoencephalitis using an oral lipid nanosystem

“…Thus, dissolution testing to evaluate a drug release profile is a key factor to establish the effective bioavailability of orally administered drugs. Accordingly, two factors-solubility and gut permeability-are responsible for bioavailability of the drug (Löbenberg et al, 2020). Flubendazole (FLZ) is an anthelmintic drug that belongs to Class II of the Biopharmaceutics Classification System (BCS) and is indicated as a potential candidate in drug repositioning in treating several types of cancer (Králová et al, 2013) and meningoencephalitis (Nixon et al, 2018).…”